Shares of Mind Medicine (MindMed) Inc. (MNMD) surged by a remarkable 21.01% on Thursday, November 8th, driven by the company's better-than-expected quarterly results and bullish actions from analysts.
MindMed, a leading player in the emerging field of psychedelic drug development, reported an adjusted loss of $0.27 per share for the quarter ended September 30. This figure came in narrower than analysts' expectations of a $0.28 per share loss, surprising investors and sparking enthusiasm about the company's performance.
Following the earnings release, several analysts raised their price targets and ratings on MindMed, further fueling the stock's rally. Canaccord Genuity boosted its price target to $16 from $14, while maintaining a Buy rating on the shares. Similarly, RBC Capital Markets increased its target to $21 from $20, also reiterating its Outperform rating.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。